Observational Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jan 14, 2021; 27(2): 208-223
Published online Jan 14, 2021. doi: 10.3748/wjg.v27.i2.208
Table 2 Montreal classification and activity scores at enrollment by inflammatory bowel diseases type and geographic region
CD classification
CD patients (n = 264)
Southeast (n = 196)
South (n = 34)
Northeast/Midwest (n = 34)
Location1
L1-ileal67 (25.4)50 (25.5)10 (29.4)7 (20.6)
L2-colonic42 (15.9)26 (13.3)5 (14.7)11 (32.4)
L3-ileocolonic150 (56.8)116 (59.2)18 (52.9)16 (47.1)
L4-upper GI tract disease17 (6.4)11 (5.6)2 (5.9)4 (11.8)
Behavior
B1-Nonstricturing/nonpenetrating58 (22.0)33 (16.8)9 (26.5)16 (47.1)
B2-Stricturing110 (41.7)89 (45.4)14 (41.2)7 (20.6)
B3-Penetrating91 (34.5)70 (35.7)10 (29.4)11 (32.4)
Perianal disease105 (39.8)87 (44.4)12 (35.3)6 (17.6)
HBI score2.0 [0-37]2.0 [0-37]2.0 [0-17]3.5 [0-12]
Missing343202
CDAI137.0 [-25-495]141.0 [-25-495]NA93.0 [-22-292]
Missing1871373416
Active CD2118 (44.7)89 (45.4)13 (38.2)16 (47.0)
HBI ≥ 8 or CDAI ≥ 22046 (17.4)UNKUNKUNK
Fecal calprotectin > 200 μg/g40 (15.2)UNKUNKUNK
Colonoscopy result suggestive of disease activity during the previous year69 (26.1)UNKUNKUNK
UC classificationUC patients (n = 143)Southeast (n = 94)South (n = 21)Northeast/Midwest (n = 28)
Extension
E1-distal UC43 (30.1)27 (28.7)8 (38.1)8 (28.6)
E2-left-sided26 (18.2)12 (12.8)2 (9.5)12 (42.9)
E3-pancolitis74 (51.7)55 (58.5)11 (52.4)8 (28.6)
Severity
S0-asymptomatic57 (39.9)36 (38.3)9 (42.9)12 (42.9)
S1-mild UC32 (22.4)25 (26.6)3 (14.3)4 (14.3)
S2-moderate UC40 (28.0)25 (26.6)7 (33.3)8 (28.6)
S3-severe UC14 (9.8)8 (8.5)2 (9.5)4 (14.3)
Mayo endoscopic subscore (n = 71)
Normal16 (22.5)9 (19.1)1 (12.5)6 (37.5)
Mild disease18 (25.4)13 (27.7)2 (25.0)3 (18.8)
Moderate disease28 (39.4)20 (42.6)3 (37.5)5 (31.3)
Severe disease9 (12.7)5 (10.6)2 (25.0)2 (12.5)
Missing72471312
Total Mayo score2.0 [0.0-10.0]3.0 [0.0-9.0]2.5 [0.0-10.0]2.0 [0.0-8.0]
Missing72471312
Partial Mayo score1.0 [0.0-9.0]1.5 [0.0-9.0]1.0 [0.0-9.0]1.5 [0.0-8.0]
Active UC236 (25.2)19 (20.2)5 (23.8)12 (42.9)

  • Citation: Zaltman C, Parra RS, Sassaki LY, Santana GO, Ferrari MLA, Miszputen SJ, Amarante HMBS, Kaiser Junior RL, Flores C, Catapani WR, Parente JML, Bafutto M, Ramos O, Gonçalves CD, Guimaraes IM, da Rocha JJR, Feitosa MR, Feres O, Saad-Hossne R, Penna FGC, Cunha PFS, Gomes TN, Nones RB, Faria MAG, Parente MPPD, Scotton AS, Caratin RF, Senra J, Chebli JM. Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(2): 208-223
  • URL: https://www.wjgnet.com/1007-9327/full/v27/i2/208.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v27.i2.208